FIELD: pharmacology.
SUBSTANCE: invention relates to a dipeptide containing a nonproteinogenic amino acid of formula 1 
, and a method of obtaining of the target polypeptide or protein, including one or more nonproteinogenic amino acids, where the specified dipeptide of formula 1 is used.
EFFECT: dipeptide has a high stability, is easy to handle and its use in the peptide chemistry is easier compared to a conventional stepped peptide synthesis in the solid phase by reducing the number of stages of chemical modification, such as protection removal and activation stages.
19 cl, 1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DOUBLE-ACYLATED GLP-1 DERIVATIVES | 2010 |
|
RU2559540C2 |
| ORAL DOSING OF GLUCAGON-LIKE PEPTIDE-1 COMPOUNDS | 2014 |
|
RU2671406C2 |
| GLUCAGON-LIKE PEPTIDE-1 (GLP-1) DERIVATIVES | 2004 |
|
RU2401276C2 |
| SOLID COMPOSITIONS CONTAINING AGONIST TO GLP AND SALT OF N-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | 2011 |
|
RU2600440C2 |
| SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID SALT AND LUBRICANT | 2019 |
|
RU2807183C2 |
| SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID SALT | 2019 |
|
RU2804318C2 |
| GLP-1 PEPTIDES COMPOSITIONS AND THEIR PRODUCTION | 2013 |
|
RU2641198C2 |
| ACYLATED GLP-1 COMPOUNDS | 2006 |
|
RU2434019C2 |
| NOVEL GLUCAGON ANALOGUES | 2012 |
|
RU2610175C2 |
| NOVEL GLUCAGON ANALOGUES | 2011 |
|
RU2559320C2 |
